86 results about "Prostaglandin" patented technology

The invention discloses an anti-drunkenness composition and application thereof. The invention provides an application of a composition in preparation of an anti-drunkenness product, the composition contains edible plasma powder, xylitol, fructo-oligosaccharide, microcrystalline cellulose, mogroside and magnesium stearate, and the edible plasma powder contains immune globulin IgG. The TZK provided by the invention has obvious regulation and improvement effects on sleep behaviors, serum indexes and gastrointestinal injury after acute drinking. The oxidative stress state after long-term large-dose chronic drinking is effectively adjusted, so that the oxidative stress injury index malondialdehyde (MDA) gradually returns to the normal level; according to the present invention, the activity of the liver injury markers such as alanine transaminase (ALT) and aspartate transaminase (AST) is reduced, the liver protection effect is provided, and the gastric mucosa structure repair is promoted by increasing the gastric mucosa prostaglandin content and reducing the local MDA level;

This invention provides a method for the simultaneous and rapid detection of four oxidative stress-related biomarkers and its application. The detection method includes: (S1) pretreatment of samples using a protein precipitation extract to simultaneously extract four target compounds: 8-hydroxydeoxyguanosine, 8-isoprostaglandin F2β, 8-isoprostaglandin F2α, and acetyllysine, and preparing a test solution; the protein precipitation extract is a methanol-acetonitrile-perchloric acid mixed solution containing formic acid, wherein the volume ratio of methanol, acetonitrile, and perchloric acid is (8-10):(8-10):(0.5-1), and the volume concentration of formic acid is 0.1-0.5%; (S2) detection of the test solution and standard solution using liquid chromatography-tandem mass spectrometry, and matrix calibration using an internal standard method; plotting a standard curve with the peak area ratio of the target compound to the internal standard as the ordinate and the concentration as the abscissa; and calculating the concentration of the target compound in the test solution based on the standard curve.

Provided are intermittent administration methods for reducing toxicity in the treatment of conditions associated with increased 15-hydroxyprostaglandin dehydrogenase (15-PGDH) activity or expression levels in a subject with a 15-PGDH inhibitor. Further, provided herein are methods of treating a condition associated with increased 15-hydroxyprostaglandin dehydrogenase (15-PGDH) activity or expression level in a subject by administering a 15-PGDH inhibitor while maintaining the therapeutic effect of the 15-PGDH inhibitor when the plasma concentration of the 15-PGDH inhibitor in the subject drops below the EC50 of the 15-PGDH inhibitor.

The invention provides a special culture medium for prostate cancer organoid and a culture method thereof, and belongs to the technical field of biological medicines. The special culture medium for the prostatic cancer organoid is composed of a basic culture medium and a culture additive, and the basic culture medium does not contain exogenously added Noggin recombinant protein and R-spondin recombinant protein. The culture additive is prepared from a basic fibroblast growth factor, a keratinocyte growth factor, a fibroblast growth factor 10, insulin, a p38MAPK signal channel inhibitor, an insulin-like growth factor 1, B27, nicotinamide, N-acetylcysteine, hydrocortisone, a ROCK kinase inhibitor, retinoic acid, interleukin 6, prostaglandin E2, a eriocin and androgen. According to the special culture medium for the prostatic cancer organoid, the culture success rate is increased while the cost is reduced.

A drug-polymer conjugate, which is a copolymer of at least one monomer of formula (I) where: X may be the same or different at each occurrence and represents a terminal functional group comprising an alkyne or an azide; Q is independently selected at each occurrence and may be present or absent and when present, represents a linking group; R is selected from the group consisting of linear or branched hydrocarbon, optionally substituted aryl and optionally substituted heteroaryl; D is a releasable bicyclic prostaglandin; L is a linker group; and at least one co-monomer of Formula III J-(Y1-A)n, J represents a linking functional group, n is 2 to 8 preferably 3 to 8; Y1 comprises a polyether of formula (ORa)m wherein Ra is independently ethylene, propylene and butylene and m is from 1 to 300 (preferably 2 to 300) and the polyether is in chain with one or more groups which are preferably selected from one or more of optionally substituted straight or branched C1 to C10 alkylene, amino, ether, ester, amide, carbonate and carbamate; A may be the same or different at each occurrence and represents a group comprising a terminal functional group comprising an alkyne or an azide functionality, wherein said terminal functional group is complementary to the terminal functional group X of formula (I) providing triazole moieties from reaction of X and A.

The invention discloses blood filtration replacement liquid as well as a preparation method and application thereof. The displacement liquid comprises low molecular weight heparin calcium, prostaglandin E1, prostacyclin, electrolyte with specific concentration, glucose and an interleukin-1 receptor antagonist. The preparation method comprises the following steps: weighing the raw materials according to the proportion, dissolving to a constant volume, removing pyrogen and heat, and carrying out aseptic packaging. During clinical application, replacement liquid and blood are filtered according to the replacement rate of 1: 1-2: 1 according to the condition of a patient, 4-6 hours each time and 2-3 times each week, and related indexes are monitored. Animal tests show that the replacement liquid has good safety under the effective dosage, and has potential influence on part of organs under the high dosage. A stability test shows that the compound can be stably stored under a certain condition. The invention provides the replacement liquid which can achieve anticoagulation and blood vessel protection, maintain electrolyte balance and relieve inflammatory response, is expected to improve the prognosis of hemodialysis patients, and has important clinical significance and wide application prospects.

The present disclosure relates to genetically modified host cells producing prostaglandins, to genetic constructs for expression of such mutants; to cultures of the genetically modified host cells and its use to produce the said products; to fermentation liquids comprising the said products resulting from such production; to compositions comprising the fermentation liquid; to pharmaceutical preparations made from such compositions and to the uses of such compositions and preparations.

This invention relates generally to compositions and methods for preventing, reducing the occurrence of or treating a headache in a subject in need thereof. In particular, the present invention relates to methods for enhancing 2-arachydonyl glycerol (2AG) tone and reducing prostaglandin activity in a subject for purposes of preventing, reducing the occurrence of or treating a headache (e.g., a migraine headache) in a subject.

The invention belongs to the technical field of drug delivery and tumor immunotherapy, and particularly relates to an oncolytic virus vesicle as well as a preparation method and application thereof. The preparation method comprises the following steps: co-incubating oncolytic adenovirus and platelets in a buffer system containing prostaglandin E2, and inducing to form an inner membrane encapsulation body; and activating and releasing the vesicles under the conditions of 36-38 DEG C and 4-6% CO2, and carrying out gradient centrifugal collection of 300g, 2000g, 10000g and 100000g. The particle size of the oncolytic virus-loaded vesicle is 50-200nm, the surface of the oncolytic virus-loaded vesicle contains CD41, CD61 and P-selectin, and the oncolytic virus-loaded vesicle can realize long circulation and lung targeting delivery of oncolytic viruses, is suitable for preparing drugs for treating breast cancer and breast cancer lung metastasis, and has a remarkable tumor inhibition effect.

This invention relates to a method for preparing black ginseng concentrate and the black ginseng concentrate prepared by the above method. The method for preparing black ginseng concentrate is characterized by comprising the following steps: placing red ginseng in a continuous steam-drying machine to prepare black ginseng by steaming, cooling and drying; adding alcohol to the black ginseng powder prepared above and extracting and filtering to prepare black ginseng extract; and concentrating and heat-treating the prepared black ginseng extract using a plate evaporator.

Methods for the synthesis of a tricyclic-prostaglandin D2 metabolite methyl ester or a pharmaceutically acceptable salt thereof.

Sulfonyl-azole compounds (e.g., sulfonyl-imidazole compounds) and their use as covalent ligands for reactive nucleophilic amino acid residues in proteins, such as reactive tyrosines, e.g., to selectively form modified proteins and / or to alter the biological activity of the proteins are described. Sulfonyl-imidazole compounds for inhibiting particular proteins, such as prostaglandin reductase 2 (PTGR2) and glutathione S-transferase (GST) enzymes, are also described.

The application belongs to the technical field of microorganisms, and provides a Streptococcus salivarius subsp. thermophilus HX-ST36, which has a preservation number of CGMCC NO. 32955. The Streptococcus salivarius subsp. thermophilus provided by the application can ferment Astragalus membranaceus Bunge-Angelica sinensis. In a cold coagulation and blood stasis type primary dysmenorrhea model mouse, the fermentation product thereof can significantly inhibit the writhing response, and can realize the effects of relieving dysmenorrhea and tonifying blood by reducing the levels of prostaglandin PGF2 and vasopressin ADH in uterine tissue and increasing the hemoglobin (HGB) content. The effect of the fermentation product in removing dampness is verified by improving the dampness signs of a crowd. The application further provides a probiotic preparation and a preparation method of a probiotic fermentation product. The preparation method of the probiotic preparation and the probiotic fermentation product is simple and can be produced on a large scale.

The invention relates to the technical field of metabonomics analysis, in particular to application of a metabolic marker in preparation of a head and neck squamous cell carcinoma diagnostic product, a kit, a screening method of the metabolic marker of the head and neck squamous cell carcinoma, a diagnostic model and a construction method and application of the diagnostic model. The metabolic marker comprises at least one of lactic acid, sphingosine, cadaverine, uridine diphosphate, allantoic acid, hydroxyproline, sphingosine-1-phosphoric acid, indole-3-acetaldehyde, pantothenic acid, fumaric acid, malic acid, prostaglandin or ornithine in red blood cells and / or plasma. The screened red blood cells and plasma metabolism markers can be used for predicting or diagnosing the head and neck squamous cell carcinoma respectively or independently, particularly, the red blood cell metabolism markers can provide more stable tumor microenvironment information, and the metabolism stability is high and is not easily influenced by diet and circadian rhythm.

Disclosed herein are compounds that can inhibit 15-hydroxyprostaglandin dehydrogenase. Such compounds may be administered to subjects that may benefit from modulation of prostaglandin level.

TIFF2023512405000068.tif97170 The present invention relates to a process for preparing a chiral prostaglandin enol intermediate of Formula 1, comprising the steps of separating a compound of Formula 16-(R,S)-10 into its diastereomers by fractional crystallization, reducing the 15-oxo group of the compound of Formula 16-(R)-10 to obtain a compound of Formula 15-(R,S),16-(R)-11, subsequently removing the protecting group of the compound of Formula 15-(R,S),16-(R)-11, isolating the compound of Formula 1, and optionally crystallizing the compound of Formula 1. Optionally, undesired isomers formed during fractional crystallization can be epimerized, and additional amounts of the desired isomer can be recovered from the resulting mixture. The present invention also provides novel intermediates useful in this process. The present invention further relates to a process for the fractional crystallization of the compound of formula 16-(R,S)-10.

This invention discloses a rifaximin nanoemulsion, its preparation method, and its application, belonging to the field of veterinary drug technology. The technical solution includes a rifaximin nanoemulsion comprising rifaximin, a compound essential oil, a surfactant, a co-surfactant, and water; the compound essential oil includes oregano oil, cinnamon oil, and tea tree oil. This invention prepares a rifaximin nanoemulsion using a compound of oregano, cinnamon, and tea tree oils as the oil phase, exhibiting both high antibacterial efficiency and high safety. The three essential oils have a synergistic antibacterial effect, complementing rifaximin through multi-target action, broadening the antibacterial spectrum, and showing significant inhibitory effects against various bacteria and fungi. It can enhance uterine smooth muscle contraction function by stimulating the synthesis and secretion of prostaglandins and oxytocin, providing potential support for uterine involution and endometrial repair. After administration, it can effectively reduce the number of inflammatory cells such as leukocytes and neutrophils in experimental dairy cows, significantly reduce purulent vaginal discharge, and restore the softness and elasticity of the uterus upon rectal examination.

The disclosure provides compounds of Formula 1, and the pharmaceutically acceptable salts thereof. The variables in Formula 1, e.g. X1-X5, A1, A2, and R1-R4 are described herein. Such compounds are useful as prostaglandin transport (PGT) inhibitors. The disclosure further includes pharmaceutical compositions comprising a compound of Formula 1 or salt thereof and methods of using compounds of Formula 1 and salts thereof to treat diseases and disorders mediated, at least in part, by prostaglandin levels or cyclooxygenase activity. Such diseases and disorders include painful and inflammatory conditions.

The application discloses a culture medium for constructing a gastric cancer ovary metastasis microtumor model and application. The application relates to the technical field of biotechnology, and provides a culture medium for constructing a gastric cancer ovary metastasis microtumor model, which is composed of three antibacterial and antifungal agents, HEPES, GlutaMax, human recombinant protein EGF, bFGF, HGF, FGF-10, Wnt-3a, Noggin, R-spondin 1, Follistatin, CHIR99021, SB202190, A83-01, Primocin, N-acetyl-L-cysteine, nicotinamide, N2 additives, cholera toxin, B27, ITS-X, Y-27632, gastrin, prostaglandin E2, beta-estradiol, progesterone, Galunisertib and a basic culture medium. The culture success rate of the gastric cancer ovary metastasis microtumor model is effectively improved.

To provide a drug delivery system for treating glaucoma or related conditions.SOLUTION: Provided is a drug delivery system comprising (1) a prostaglandin, a CNTF compound, a TNF-α / TNFR inhibitor, a FAS or FASL inhibitor, or any combination thereof, and (2) a sustained delivery component.SELECTED DRAWING: None

A polymer-prostaglandin conjugate comprising: a polymer backbone comprising a plurality of groups of formula (I): wherein: T represents a triazole group; q is independently selected at each occurrence and may be present or absent and when present represents a linking group; r is selected from the group consisting of linear or branched hydrocarbons; d is selected from prostaglandin; and L is a group of formula (II) wherein R5 is selected from hydrogen and C1 to C6 alkyl; (R) represents a terminal of a group bonded to the R group; and (D) represents a terminal of a group attached to the group D.

This utility model discloses a prostaglandin vaginal capsule forming machine, relating to the technical field of capsule forming machines. It includes a support plate, with a slurry forming machine for producing prostaglandin vaginal capsules mounted on the top rear end of the support plate. The slurry forming machine has external auxiliary components for cutting. These auxiliary components include a mounting bracket mounted on the support plate, located at the front of the slurry forming machine. This utility model uses a dual-axis motor to drive a movable bracket, which is limited by a positioning bracket. The movable bracket then drives a cutter to cut the capsule. Because the unloading plate and the cutter move in contact, the slurry adhering to the cutter is pushed off by the unloading plate. Furthermore, because the unloading plate is supported by a telescopic rod and a spring, it can slowly push the slurry, avoiding excessive pressure that could scatter the slurry or hinder subsequent capsule forming. This prevents the slurry from adhering to the outside of the cutter, thus avoiding affecting the feeding efficiency and cutting effect.

Provided herein are methods for reducing reactive microglia in a subject. Further provided herein are methods for treating a neurological disease, disorder, or condition in a subject. In some cases, the methods involve administering a 15-hydroxyprostaglandin dehydrogenase (15-PGDH) inhibitor to the subject. In some cases, the 15-PGDH inhibitor can penetrate the blood-brain barrier.

This invention discloses the application of prostaglandin A2 in the preparation of drugs for treating anxiety disorders and the related pharmaceutical formulation. It belongs to the field of biomedical technology, and specifically relates to the application of prostaglandin A2 in the preparation of drugs for treating anxiety disorders. Through chronic restraint stress (CRS) mouse models, corticosterone-induced (CORT)-damaged PC12 cell models, and multi-level molecular, circuit, and behavioral analyses, this invention demonstrates that prostaglandin A2 can exert multi-target anti-anxiety effects at the levels of overall behavior, cellular function, neural circuit structure, and molecularity. Prostaglandin A2 can treat anxiety disorders by improving anxiety-like behaviors and reversing behavioral phenotypic damage.

The invention relates to the field of cosmetology, dermatology and medicine, and is concerned with the development and production of a combination, and also of a composition based thereon, for hair growth enhancing in mammals and / or for preventing and / or treating alopecia, primarily in humans, and more particularly to combinations based on derivatives of F- and E-type prostaglandins, characterized by the absence of undesirable side-effects, and also to a stable composition comprising said combination. The use of a combination of prostaglandins in a single composition makes it possible to simultaneously activate a plurality of physiological processes, including stimulating a hair follicle to produce a new hair, increasing the local microcirculation in the area adjacent to the hair follicle, and reducing the aggregation of thrombocytes, thereby preventing thrombogenesis in the capillary network. Furthermore, the presence in the combination or in the composition based thereon of modified prostaglandins carrying a group of nitrogen oxide donors enables better penetration of other ingredients of the combination or composition into the skin.

There are described compositions comprising an effective amount of a combination of two or more components, said components selected from acacetin, ACTI peptide, alpha-lipolic acid, alprostadil, anisomycin, apigenin, ascorbic acid, astragalus, berberine, β-lapachone, β-hydroxy-beta-methyl-butyrate, Bacopa monnieri, catechin, catechol, chamomile, chrysin, coumestrol, curcumin, dinitrophenol, dinoprost, ellagic acid, (−)-epigallocatechin gallate, green tea extract, fisetin, genistein, ginsenoside RE, glabridin, 18-α-glycyrrhetinic acid, 18-β-glycyrrhetinic acid, glycyrrhizin, hydroquinone, isoquercitrin (EMIQ), kaempferol, kuromanin, leucine, lithium, luteolin, luteolin, luteolinidin, melatonin, menadione, 1-methylnicotinamide (MNA), methyl salicylate, myricetin, nadide, niacin (vitamin B3), nicotinamide (NAM), nicotinamide mononucleotide (NMN), nicotinamide riboside (NR), nicotinic acid adenine dinucleotide (NaAD), nicotinic acid mononucleotide (NaMN), parsley (Petroselinium crispum), phenylephrine, pokeweed mitogen, 15-Δ prostaglandin J2, puromycin, quercetin, quinolinic acid, retinoic acid, trichostatin A, troxrutin, rutin, tryptophan, vitamin D3, withaferin A, wortmannin and zinc (including salts thereof).

A companion diagnostic method, kit, and integrated system for quantifying expression of Prostaglandin Reductase 1 (PTGR1) in a patient sample are disclosed. When the measured expression equals or exceeds a predetermined threshold, the patient is selected to receive hydroxyurea methylacylfulvene (LP-184) or a related acylfulvene. The invention enables personalized cancer therapy, improves objective response rates, and minimizes unnecessary exposure to ineffective treatment. Also provided are pharmaceutical combinations, uses, and claims for treating PTGR1 -positive solid tumors and hematological malignancies.